A consortium led by CardiacBooster, in partnership with Fire1 and Integer, received $10.8 million (€9.3 million in funding) recently.
The funding, from Ireland’s Disruptive Technologies Innovation Fund (DTIF), supports the development of CardiacBooster’s unique mechanical cardiac support technology into a comprehensive medical device platform for treating cardiogenic shock.
Related: Apreo Health raises $130m to fund emphysema implant pivotal trial
Ireland’s DTIF, established under its National Development plan, aims to invest in “bold ideas and ambitious collaborative partnerships.” This consortium aims to bring significant innovation to an indication with high mortality rates. The companies hope to improve health outcomes and prevent loss of life with new therapeutic tools.
The project, called Ventripump, seeks to validate the Ventripump device as the gold standard for cardiogenic shock treatment.
CardiacBooster, based in the Netherlands and Ireland, is a spin-off from the Radboud University Medical Center (Nijmegen, Netherlands). The minimally invasive cardiac support device developer has offices in Nijmegen as well as in Galway, Ireland. It develops the high-flow, low-profile percutaneous ventricular assist device (pVAD) called Ventripump. The company says its mission is to develop an effective, minimally invasive cardiac assist device which provides powerful ventricular support while maintaining a deliverable catheter profile.
Ventripump allows for effective hemodynamic support while minimizing procedure invasiveness for cardiogenic shock and high-risk percutaneous coronary intervention (PCI). The mechanical pVAD support device aims to ensure adequate systemic blood flow while unloading the heart.
Several companies offer ventricular assist devices, including percutaneous, mechanical ones. Supira Medical earlier this year brought in $120 million to support its pVAD. Abbott dominates the left ventricular assist device (LVAD) space with its HeartMate 3 system. However, companies like CorWave, BrioHealth and FineHeart are looking to penetrate that market as well.
